This finding could have therapeutic implications given the ongoing evaluation of PI3K inhibitors in clinical trials as well as the potential benefit of aspirin therapy in CRC patients harboring PIK3CA mutations [9]. This evidence concerns the gene PIK3CG and colorectal carcinoma.